Connect with us

World News

Russia presents EpiVacCorona to WHO, their new covid-19 vaccine after Sputnik V



EpiVacCorona  is the new Covid-19 vaccine developed by Russia after Sputnik V.

Eclipsed by the development of the Gamaleya Research Institute of Epidemiology and Microbiology, a new and second vaccine against COVID-19 was presented this week by Russian authorities.

One of the most advanced vaccines in the world against the new coronavirus that produces the COVID-19 disease is Sputnik V developed by Russia that President Vladimir Putin himself presented to the planet on August 11, without yet having approved the crucial and definitive clinical phase III, which involves monitoring tens of thousands of people.

The vaccine, which is already being applied in Russia, will be the first to arrive in Argentina, as announced by President Alberto Fernández himself last Thursday that the Government signed the contract for the acquisition of the first doses of the Sputnik V vaccine against SARS-CoV-2 coronavirus. The announcement signifies a certain step towards the arrival of the first vaccines against the virus that generates the COVID-19 disease, which in our country has already caused almost 1.5 million infections and 40,600 deaths in just 9 months from arrival in our country. country on March 3 last.

But the advanced Sputnik V vaccine, the only inoculation to be made with a human adenovirus technology of two different vectors, Ad5 and Ad26, for a first and a second injection and that does not contain live human adenoviruses, but human adenoviral vectors that are not capable multiplying and are completely safe for health, it is not the only one that Russian scientists have created to combat the coronavirus.

Russia has sent this week to the World Health Organization (WHO) the documentation of the second vaccine against COVID-19 registered in its country, called EpiVacCorona. This was confirmed last Wednesday by the Russian health chief, Anna Popova: “ On December 8 the documentation of another Russian vaccine was sent to the WHO. It is the EpiVacCorona. We are waiting for the WHO’s decision ”on its registration, Popova said at a conference on the fight against COVID-19 and other infectious diseases, according to the Interfax agency.

EpiVacCorona was developed at the Véktor Siberian scientific center, under the Russian Agency for Consumer Defense (Rospotrebnadzor), which Popova runs. According to its creators, the vaccine guarantees immunity for at least 6 months, can be administered on several occasions and does not cause allergic reactions, as established in tests with animals and people, since it has been made from synthesized particles of the new coronavirus artificially. “About 1,000 people have received this vaccine in the framework of clinical trials and all the volunteers feel fine,” Popova added.

Russian Deputy Prime Minister Tatyana Alekseevna Golikova also referred to the new development: “I want to point out that clinical studies were carried out on 100 volunteers. Unlike the first Russian Sputnik V vaccine, which is a vector vaccine, that is, produced based on adenovirus, the new vaccine was created on the basis of one of the promising synthetic platforms, it is a peptide vaccine, it consists of short fragments of artificially synthesized viral proteins called peptides , through which the immune system learns and subsequently recognizes and neutralizes the virus. I must say that the vaccine is characterized by the absence of reactogenicity and a sufficiently high level of safety ”.

“We believe that it can be applied to the elderly and to patients with chronic diseases,” Popova said shortly after the EpiVacCorona was registered last October by the Russian Ministry of Health.

CEO Rinat Maksyutov told a virtual conference: “The expected advantage of this vaccine compared to other vaccine platforms is its effectiveness against antigenically evolving strains , as it contains conservative SARS-COV-2 epitopes. It is very safe, simple to produce and has stability in its components providing an advantage when it is stored or transported to the vaccination units ”.

EpiVacCorona is scheduled to enter civil circulation during January 2021, according to data from the vaccine registration certificate published in the state drug registry. The State Research Center for Virology and Biotechnology “Vector”, created in 1974, is one of the largest virological and biotechnological scientific centers in Russia.


Breaking News: Russia and Iran have obtained U.S voting registration information

“I want to buy new boots” – A mother from Russia, who tried to sell her one-week-old daughter for $3,794 revealed

JUST IN: Russian President Vladimir Putin has approved a Covid-19 vaccine

“Covid-19 Vaccination nationalism is advancing at high speed” – United Nations General António Guterres warns

Who is Alexei Navalny – Russian anti-corruption activist rushed to the hospital in an unconscious state

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


World News

Local News